{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:58:39Z","timestamp":1780714719879,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00105-020-04675-3","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T18:04:42Z","timestamp":1598551482000},"page":"249-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapie von Urtikaria und atopischer Dermatitis bei einer Patientin mit Dupilumab","Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab"],"prefix":"10.1007","volume":"72","author":[{"given":"Julia","family":"F\u00f6hr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigbert","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"4675_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/ddg.13531","volume":"16","author":"M Maurer","year":"2018","unstructured":"Maurer\u00a0M, Zuberbier\u00a0T, Siebenhaar\u00a0F et\u00a0al (2018) Chronische Urtikaria \u2013 Was bringt die neue Leitlinie? J\u00a0Dtsch Dermatol Ges 16:584\u2013593","journal-title":"J Dtsch Dermatol Ges"},{"key":"4675_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaip.2016.09.029","volume":"5","author":"J Sanchez","year":"2017","unstructured":"Sanchez\u00a0J, Amaya\u00a0E, Acevedo\u00a0A et\u00a0al (2017) Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: associated risk factors. J\u00a0Allergy Clin Immunol Pract 5:464\u2013470","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4675_CR3","first-page":"433","volume":"17","author":"W Grobe","year":"2019","unstructured":"Grobe\u00a0W, Bieber\u00a0T, Novak\u00a0N (2019) Pathophysiologie der atopischen Dermatitis. J\u00a0Dtsch Dermatol Ges 17:433\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"key":"4675_CR4","first-page":"1141","volume":"17","author":"E Mellerowicz","year":"2019","unstructured":"Mellerowicz\u00a0E, Weller\u00a0K, Zuberbier\u00a0T et\u00a0al (2019) Therapie von Patienten mit cholinergischer Urtikaria im Alltag in deutschsprachigen L\u00e4ndern. J\u00a0Dtsch Dermatol Ges 17:1141\u20131149","journal-title":"J Dtsch Dermatol Ges"},{"key":"4675_CR5","doi-asserted-by":"publisher","first-page":"100097","DOI":"10.1016\/j.waojou.2019.100097","volume":"13","author":"MN Ghanzafar","year":"2020","unstructured":"Ghanzafar\u00a0MN, Kibsgaard\u00a0L, Thomsen\u00a0SF et al (2020) Risk of comorbidities in patients diagnosed with chronic urtikaria: a nationwide registry-study. World Allergy Organ\u00a0J 13:100097","journal-title":"World Allergy Organ J"},{"key":"4675_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151","author":"A Le Floc\u2019h","year":"2019","unstructured":"Le Floc\u2019h\u00a0A, Alline\u00a0J, Nagashima\u00a0K (2019) Dual blockade of IL\u20114 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. https:\/\/doi.org\/10.1111\/all.14151","journal-title":"Allergy"},{"key":"4675_CR7","first-page":"1","volume":"12","author":"AJ Hendricks","year":"2019","unstructured":"Hendricks\u00a0AJ, Yosipovitch\u00a0G, Shi\u00a0VY (2019) Dupilumab use in dermatologic conditions beyond atopic dermatitis\u2014a\u00a0systemic review. J\u00a0Dermatolog Treat 12:1\u201310","journal-title":"J Dermatolog Treat"},{"key":"4675_CR8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","volume":"7","author":"JK Lee","year":"2019","unstructured":"Lee\u00a0JK, Simpson\u00a0RS (2019) Dupilumab as a\u00a0novel therapy for difficult to treat chronic spontaneous urticaria. J\u00a0Allergy Clin Immunol Pract 7:1659\u20131661","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4675_CR9","first-page":"1150","volume":"17","author":"T Bieber","year":"2019","unstructured":"Bieber\u00a0T (2019) Neuartige Therapien auf der Grundlage der Pathophysiologie der atopischen Dermatitis. J\u00a0Dtsch Dermatol Ges 17:1150\u20131161","journal-title":"J Dtsch Dermatol Ges"},{"key":"4675_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/ced.14081","volume":"45","author":"S Ferruci","year":"2020","unstructured":"Ferruci\u00a0S, Benzevry\u00a0V, Berti\u00a0E et\u00a0al (2020) Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment. Clin Exp Dermatol 45:345\u2013346","journal-title":"Clin Exp Dermatol"},{"key":"4675_CR11","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jaip.2018.01.034","volume":"6","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg\u00a0A, Ariens\u00a0L, Thurau\u00a0S et\u00a0al (2018) Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab\u2014clinical characteristics and treatment. J\u00a0Allergy Clin Immunol Pract 6:1778\u20131780","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04675-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-020-04675-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04675-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T23:12:07Z","timestamp":1630019527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-020-04675-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["4675"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04675-3","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]},"assertion":[{"value":"27 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Jahn hat mehrj\u00e4hrig im Pharmaunternehmen Sanofi gearbeitet und die Markteinf\u00fchrung von Dupilumab als Leiter Medical Affairs begleitet. J.\u00a0F\u00f6hr und M.\u00a0Herbst geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die die Patientin zu identifizieren sein k\u00f6nnte, liegt von ihr eine schriftliche Einwilligung vor. Die Anwendung der hier beschriebenen Biologika erfolgte gem\u00e4\u00df Fachinformation. Die Patientin wurde sorgf\u00e4ltig \u00fcber das Nutzen-Risiko-Verh\u00e4ltnis aufgekl\u00e4rt und hat eine Einwilligung unterzeichnet.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}